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Abstract
Production of the androgen testosterone is controlled by a negative feedback loop within
the hypothalamic-pituitary-gonadal (HPG) axis. Stimulation of testicular Leydig cells by pitu-
itary luteinising hormone (LH) is under the control of hypothalamic gonadotrophin releasing
hormone (GnRH), while suppression of LH secretion by the pituitary is controlled by circulat-
ing testosterone. Exactly how androgens exert their feedback control of gonadotrophin se-
cretion (and whether this is at the level of the pituitary), as well as the role of AR in other
pituitary cell types remains unclear. To investigate these questions, we exploited a trans-
genic mouse line (Foxg1Cre/+; ARfl/y) which lacks androgen receptor in the pituitary gland.
Both circulating testosterone and gonadotrophins are unchanged in adulthood, demonstrat-
ing that AR signalling is dispensable in the male mouse pituitary for testosterone-dependent
regulation of LH secretion. In contrast, Foxg1Cre/+; ARfl/y males have a significant increase
in circulating prolactin, suggesting that, rather than controlling gonadotrophins, AR-
signalling in the pituitary acts to suppress aberrant prolactin production in males.
Introduction
Production of testosterone by testicular Leydig cells is tightly regulated by the hypothalamic-
pituitary-gonadal (HPG) axis, forming a homeostatic negative feedback loop. Gonadotrophin-
releasing hormone (GnRH), secreted by the hypothalamus, stimulates secretion of luteinising
hormone (LH) from the pituitary, which stimulates testosterone production by Leydig cells.
Testosterone then feeds back to the hypothalamic-pituitary element to negatively regulate fur-
ther LH secretion in a dose-dependent manner [1, 2]. Development of this negative feedback
loop is essential for homeostatic maintenance of circulating testosterone concentrations in
males; exactly how this is affected is not entirely understood, nevertheless androgen feedback
at the level of both the hypothalamus and the pituitary has become the widely accepted
paradigm.
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Androgens impart their effects on transcription by binding to the androgen receptor (AR)
[3]. AR is found in both the hypothalamus and pituitary in the mouse [4] suggesting androgens
are able to feedback at both locales to regulate circulating gonadotrophin levels. Indeed in Tes-
ticular Feminisation (Tfm) mice (mice with a null allele of AR and little testosterone produc-
tion [5]), levels of serum LH and follicle stimulating hormone (FSH) are increased [6]. LH
levels are also increased in humans with complete androgen insensitivity syndrome (CAIS) in
agreement with a general role for AR negative feedback in regulation of gonadotrophins [7].
Unfortunately, mouse models of global AR ablation add little to clarify how androgen feedback
acts on the HPG axis as the loss of AR throughout all cells of the HPG axis prevents assignment
of specific functional roles for androgen signalling in each cell type. Other attempts to identify
the specific site of action of feedback by testosterone on gonadotrophin secretion have been
widely explored and reveal a more complex system than androgens simply binding to AR
throughout the HPG axis. In rams and rhesus monkeys, testosterone acts by decreasing the
pulse rate of GnRH at the level of the hypothalamus but has negligible pituitary effects [1]. In
addition, data from clinical studies on patients with hypogonadotrophic hypogonadism suggest
that, while testosterone feedback is required for control of GnRH release by the hypothalamus,
aromatisation of testosterone to estradiol is sufficient for control of LH secretion by the pitui-
tary [8–10], suggesting the primary site of androgen feedback in human males is
the hypothalamus.
However, there is some evidence for a role for androgen signalling in the pituitary. Testos-
terone has been shown to suppress LH secretion in rat gonadotroph cultures [11, 12] and AR
can suppress transcription of the LHβ subunit by interacting with SF-1 [13] suggesting a key
role for androgen signalling exists at the level of the pituitary, at least in rodents.
Taken together, these data paint a confusing picture of the role of AR signalling in the pitui-
tary that is inconsistent with the widely accepted paradigm. Intriguingly, AR is widely express-
ed in several other cell populations within the pituitary in addition to the gonadotrophs [14,
15], suggesting that AR signalling may have further significant roles in the male pituitary, that
to date remain undescribed. Indeed data from a recent study has suggested a new role for pitui-
tary AR in control of glucocorticoid action [4]. This finding alone clearly demonstrates that
our current understanding of the function of androgen signalling in the pituitary
remains incomplete.
In a previous study, we utilised Foxg1-Cre to ablate AR from the caput epididymal epitheli-
um, demonstrating that local ablation of AR perturbed initial segment development, an obser-
vation confirmed by a second group using an epididymis-specific Cre Recombinase line [16].
Further investigation revealed that Foxg1-Cre is also active in the developing Rathke’s pouch
(the anlage of the pituitary) but not the hypothalamus [17–19] in this model, suggesting we
had serendipitously generated a mouse model also lacking pituitary AR. Intriguingly, circulat-
ing testosterone concentrations in this mouse model are unaffected by AR ablation [16], an ob-
servation inconsistent with the currently accepted negative-feedback paradigm. In this study,
we describe the detailed characterisation of this unique model, revealing previously unknown
functions for androgen signalling in the male pituitary with implications for our understanding
of the control of the male HPG axis.
Methods
Targeted ablation of AR from the pituitary using Foxg1-Cre mice
Mice in which AR has been ablated selectively from the pituitary were generated using Cre/
loxP technology. Male congenic 129svev mice carrying a carrying a random insertion of Foxg1-
Cre [19] were mated to C57BL/6J female mice homozygous for a floxed AR [20]. Male
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offspring were either the Foxg1Cre/+; ARfl/y mice with androgen receptor ablation or Foxg1+/+;
ARfl/y ‘control’ littermates. Foxg1+/+; AR+/y mice were also generated by mating Foxg1-Cre
stud males to C57BL/6J females to confirm that expression of Cre alone did not induce a phe-
notype. Sex and genotype ratios were all identified at the expected Mendelian ratios. Mice were
fed a soya-free diet. All mice were bred under standard conditions of care and use under li-
cenced approval from the UK Home Office (60/4200).
PCR genotyping of mice
Mice were genotyped for inheritance of Cre Recombinase as previously described [16]. PCR
amplification products were resolved using a QiaXcel capillary system (Qiagen, UK). An
amplicon of 102 bp indicated inheritance of the Cre Recombinase transgene.
Recovery of pituitaries
Mice were euthanised by inhalation of carbon dioxide and subsequent cervical dislocation
(adults) or injection of sodium pentobarbital (neonates) at 10:00h. Pituitaries were either
fixed in Bouin’s fixative (Clin-Tech, Guildford, UK) or 10% neutral buffered formalin (NBF)
for 6 hours or frozen on dry ice before being transferred to a -80°C freezer for storage. Fixed tis-
sues were processed and embedded in paraffin wax, and 5μm sections were used for histologi-
cal analysis. Sections of testis were stained with haematoxylin and eosin using standard
protocols.
Immunohistochemistry
Immunostaining was performed either by a single antibody colourimetric (DAB) immunos-
taining method, as described previously [16], or a double antibody tyramide fluorescent immu-
nostaining method, as described previously [4, 21]. Antibodies used are listed in Table 1.
Quantification of the proportion of endocrine cells expressing AR or
ESR1 in the anterior pituitary
Double immunofluorescent labelling of cell-specific pituitary hormones and either AR or ESR1
was performed on tissue sections cut from the middle of the pituitary of C57Bl6/J mice (n = 3).
Three images per section were captured using a Zeiss LSM 510 confocal microscope coupled
with LSM software (Carl Zeiss Ltd, Welwyn Garden City, UK) and used to determine colocali-
sation of AR or ESR1 with pituitary hormone products. Counting was done in Adobe
Table 1. Details of immunohistochemical staining used in these studies.
Cell Type Primary Ab Fixative
Gonadotrophs Guinea Pig anti-FSHβ (NIDDK-NIH) Bouins
Gonadotrophs Mouse anti-LHβ (Gift from Dr. W. Colin Duncan) 10% NBF
Thyrotrophs Guinea Pig anti-TSHβ (AFP3035990P, NIDDK-NIH), gift from Prof.
Alan McNeilly
Bouins
Corticotrophs Mouse anti-ACTH (#M3501, DAKO) Bouins
Somatotrophs Rabbit anti-GH (A0570, DAKO) Bouins
Lactotrophs Rabbit anti- PRL (A0569, DAKO) Bouins
AR+ve Cells Rabbit anti-AR (ab74272, Abcam) Bouins or 10%
NBF
ERα+ve cells Rabbit anti-ERα (MC-20) (Santa Cruz #sc-542) Bouins
YFP/GFP Rabbit anti-YFP/GFP (Life Technologies A-11122) Bouins
doi:10.1371/journal.pone.0121657.t001
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Photoshop. Only cells with 50% cytoplasmic staining for hormones were counted. Counts
were expressed as the percentage of hormone positive cells that were also AR/ESR1 positive.
Determination of the relative volume of endocrine cells comprising the
anterior pituitary
Three longitudinal sections per pituitary (approximately 25, 50 and 75% of the way through)
from control (n = 5) and Foxg1Cre/+; ARfl/y (n = 5) animals were analysed using a Zeiss Imager
A1 microscope (Carl Zeiss Ltd, Welwyn Garden City, UK) coupled with a Qimaging QICAM
Fast 1394 digital camera (Qimaging, Surrey, BC, Canada) and a Prior ProScan automated stage
(Prior Scientific Instrument Ltd, Cambridge, UK) driven by Image-Pro Plus 7.0 software (Med-
iaCybernetics, Rockville, MD, USA). Using the software’s stereologer plug-in, a tiled-image of
the entire pituitary section was generated, from which an area of interest (AOI; the anterior
lobe) was selected. The software then generated 50 random fields within the selected AOI. The
automatic stage was then driven between fields, placing a counting grid over the tissue. Points
falling over hormone-positive cells were counted. Between 15 and 20 fields were typically
counted to ensure a standard error (SE) for counting of<5%: SE. Only fields that were occu-
pied by50% anterior lobe were scored. The proportion of the tissue occupied by hormone
positive cells (the relative volume, RV) was then calculated as RV = (Ppi/Pt) x100
(Ppi = number of points over hormone positive cells expressed as a percentage of the total
number of points counted. Pt = Total number of points counted).
Preparation of pituitary cDNA
RNA was isolated from frozen pituitaries from n = 8 d80 Foxg1Cre/+; ARfl/y and control mice
using the RNeasy Mini extraction kit with RNase-free DNase on-the-column digestion kit
(Qiagen, Crawley, UK) according to the manufacturer’s instructions. RNA was quantified
using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
Random hexamer primed cDNA was prepared using the SuperScript VILO cDNA synthesis
kit (Life Technologies) according to manufacturer’s instructions.
Determination of deletion of AR exon 2
Evaluation of exon 2 ablation in AR mRNA was based on previously published protocols [22].
RT-PCR was performed on pituitary cDNA using BioMix Red Taq polymerase (Bioline, Lon-
don, UK) and primers located in AR exons 1 and 3 (forward AAGCAGGTAGCTCTGGGACA; re-
verse CGTTTCTGCTGGCACATAGA). PCR amplification products were resolved using a
QiaXcel capillary system (Qiagen, UK) with an amplicon of 765 bp if AR exon 2 was present
and 613 bp if exon 2 had been ablated by Cre recombinase.
Quantitative RT-PCR (qPCR)
Multiplex qPCR was performed on pituitary cDNA for the genes listed in Table 2 using an ABI
Prism 7900 Sequence Detection System (Applied Biosystems) and the Roche Universal Probe li-
brary (Roche, Welwyn, UK). Due to its high expression level, the expression of Prl was related
to an internal housekeeping gene assay for 18s rRNA (Life Technologies) whereas the expres-
sion of all other genes were related to an internal housekeeping gene assay for Actb (Roche, Wel-
wyn, UK) as described previously [23]. Resulting data were analysed using the ΔΔCt method.
AR Signalling in the Male Pituitary
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Quantification of plasma hormone levels
Immediately after culling, blood was collected from n8 control and Foxg1Cre/+; ARfl/y mice by
cardiac puncture with a syringe and needle pre-treated with heparin. Plasma was separated by
centrifugation and stored at-80. Testosterone was measured using a radioimmunoassay as pre-
viously described [24]. LH and FSH were measured using in-house designed ELISAs as previ-
ously described [25]. Commercially available ELISAs for prolactin (Abcam #ab100736), GH
(Merck Millipore EZRMGH-45K), ACTH (Antibodies Online #ABIN415571) and TSH (Anti-
bodies Online #ABIN415519) were performed according to manufacturer’s instructions. All
samples were run in duplicate in a single assay for each hormone.
Western blotting
Western blotting for ESR1 was performed as reported previously [26] on d100 control (n = 4)
and Foxg1Cre/+; ARfl/y (n = 4) pituitaries. Blots were probed with primary antibodies ESR1
(Santa Cruz sc-542) and tyrosinated TUBA (α-tubulin) isoforms (Abcam ab6160). Primary an-
tibodies were detected using donkey anti-rabbit IRDye 680RD and goat anti-rat IRDye 800CW
(LI-COR Biosciences). Detection was carried out using the LI-COR Odyssey imaging system
(LI-COR biosciences) according to manufacturer’s instructions.
Statistical analysis
Data were analysed using GraphPad Prism (version 5; GraphPad Software Inc., San Diego, CA,
USA) using a two-tailed unpaired t test with Welch’s correction (if comparing two groups) or a
one-way ANOVA with Bonferroni post-hoc test (if comparing more than two groups). Values
are expressed as means ± S.E.M. Values are stated as ‘increased’ or ‘decreased’ compared to
controls only if they are statistically significantly different.
Results
Foxg1-Cre ablates AR from the pituitary gland but circulating
testosterone levels are not affected
Breeding of R26R-EYFP female mice [27] to Foxg1-Cre males, results in Foxg1-YFP offspring
where any permanent Cre-mediated recombination event induces irreversible YFP expression
in that cell and its daughters. Immunohistochemical localisation of YFP in e12.5 embryos re-
vealed expression throughout Rathke’s pouch (the anlage of the pituitary) (Fig. 1A). Previous
Table 2. Primers and Roche UPL probes for qRT-PCR assays used in these studies.
Gene Forward primer Reverse primer Probe
Cga aaatatgcagctgtcattctgg cctttagtttacattctgggcaac 56
Fshb agacagctgactgcacagga tcacagctatggcagcagat 67
Lhb ctcagccagtgtgcacctac ggaaaggagactatggggtctac 71
Tshb aagagctggggttgttcaaa acaagcaagagcaaaaagcac 101
Pomc ggcctttcccctagagttca gacctgctccaagcctaatg 11
Gh ggaaaagcactagcctcctg gcttggcaatggctacaga 13
Prl tgttcccagcagtcaccat cagcaacaggaggagtgtcc 26
Gnrhr ggcatcaggccttctacaac tggactgattcagctgtagtttg 34
Esr1 tgcaatgactatgcctctgg ttgtagctggacacatgtagtcatt 93
Gr caaagattgcaggtatcctatgaa cttggctcttcagaccttcc 91
Cyp19a1 ccactcctgctgatcatgg tcccagacagtagccaggac 2
doi:10.1371/journal.pone.0121657.t002
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studies have demonstrated that Foxg1 is not expressed in the hypothalamus [19], as such, we
concluded that the Foxg1-Cre has utility for targeting of AR in the male pituitary. To generate
Foxg1Cre/+; ARfl/y mice, hemizygous Foxg1-Cre males are bred to homozygous ARfl/fl females
[20]. When analysed by PCR, genomic DNA of pituitaries of day (d) 2 control mice show
unrecombined AR, but almost all genomic DNA present in pituitaries of d2 Foxg1Cre/+; ARfl/y
mice is recombined by Cre recombinase to generate a null allele of AR (Fig. 1B). Adult control
mice show AR immunostaining in the pituitary, but this is completely absent in pituitaries of
Foxg1Cre/+; ARfl/y mice (Fig. 1C) demonstrating that AR ablation from fetal life is permanent,
completely abolishing any subsequent action of AR in the developing and adult pituitary. Sur-
prisingly, ablation of pituitary AR does not result in any changes to circulating testosterone
level (Fig. 1D), questioning the current paradigm of testosterone-mediated negative feedback
within the HPG axis.
AR is expressed in all anterior pituitary cell types
Prior to investigating the impact of AR ablation, double-immunofluorescence experiments
were performed on pituitaries from wild-type C57BL/6J mice to determine which endocrine
cells express AR. Localisation of cell-specific hormones and AR protein on the same tissue sec-
tion revealed all endocrine cell-types of the male anterior pituitary gland express AR
(Fig. 2A-G). The population with the highest percentage of cells expressing AR is FSH-positive
Fig 1. Foxg1-Cre recombines genomic Ar and results in loss of AR protein in Foxg1Cre/+; ARfl/y pituitaries. (A) YFP staining can be seen in the
Rathke’s pouch (arrow and magnification) of Foxg1-YFP embryos at e12.5 (B) When analysed by PCR, genomic DNA of pituitaries of d2 control mice
showed unrecombined Ar (upper band, 765 bp), but nearly all genomic Ar present in pituitaries of d2 Foxg1Cre/+; ARfl/y mice has been recombined by Cre
recombinase (lower band, 613) as seen in the complete ARKO (C) Adult control mice show AR immunostaining (red) in the pituitary, but this is completely
lost in Foxg1Cre/+; ARfl/y mice. Nuclear counterstain is blue. Scale bars are 50μm. (D) No significant difference was seen between Foxg1Cre/+; ARfl/y and
control plasma levels of testosterone.
doi:10.1371/journal.pone.0121657.g001
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Fig 2. All pituitary endocrine cell populations express AR at different percentages. Subpopulations of
(A) FSH-positive gonadotrophs (blue), (B) LH-positive gonadotrophs (blue), (C) PRL-positive lactotrophs
(blue), (D) TSH-positive thyrotrophs (E) ACTH-positive corticotrophs (F) GH-positive somatotrophs stain
positive for AR (green). Arrows point to AR positive cells and arrowheads to AR negative cells, insets show
magnifications of AR positive and negative cells, and no-primary controls. (G) When quantified, the
percentage of each endocrine cell population positive for AR was 70.7% ±2.9 for FSH-positive gonadotrophs,
61.9% ±3.0 for LH-positive gonadotrophs, 49.65% ±2.78 for PRL-positive lactotrophs, 44.97% ±6.28 for TSH-
positive thyrotrophs, 24.56% ±1.52 for ACTH-positive corticotrophs and 15.77% ±1.27 for GH-
positive somatotrophs.
doi:10.1371/journal.pone.0121657.g002
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gonadotrophs (70.7% ±2.9) followed by LH-positive gonadotrophs (61.9% ±3.0), PRL-positive
lactotrophs (49.65% ±2.78), TSH-positive thyrotrophs (44.97% ±6.28), ACTH-positive cortico-
trophs (24.56% ±1.52) and the lowest percentage of AR staining in GH-positive somatotrophs
(15.77% ±1.27).
Pituitary cell type volume does not change in Foxg1Cre/+; ARfl/y mice
Androgens acting via AR have been previously shown to have important roles in the program-
ming of multiple tissues in the developing male embryo. Therefore, any developmental conse-
quence of insufficient androgen-AR signalling during embryonic development on final
percentage cell volume of the different populations of endocrine cells in the anterior pituitary of
adult Foxg1Cre/+; ARfl/y males was assessed. No gross differences between the pituitary morphol-
ogy or size of the two groups is noted during dissection. No differences in histological morpholo-
gy are noted between control and Foxg1Cre/+; ARfl/y pituitaries. Immunohistochemistry was
performed to identify each of the pituitary cell types (Fig. 3A-F) and cell population volumes
were quantified as a percentage of the anterior pituitary total cell volume. No significant differ-
ence in the volume of the anterior pituitary occupied by the specific endocrine cell populations is
observed for PRL-positive lactotrophs (control 18.4% ±1.6, Foxg1Cre/+; ARfl/y 21.9% ±1.7), GH-
positive somatotrophs (control 12.3% ±1.6, Foxg1Cre/+; ARfl/y 11.6% ±2.3), FSH-positive gonado-
trophs (control 5.6% ±0.6, Foxg1Cre/+; ARfl/y 5.8% ±1.1), TSH-positive thyrotrophs (control 5.2%
±0.6, Foxg1Cre/+; ARfl/y 6.2% ±0.7), LH-positive gonadotrophs (control 4.8% ±0.8, Foxg1Cre/+;
ARfl/y 4.6% ±0.6), ACTH-positive corticotrophs (control 3.6% ±0.2, Foxg1Cre/+; ARfl/y 4.7% ±0.7)
when measured by stereology (Fig. 3G). Together these data suggest pituitary AR-signalling is
dispensable for the attainment of normal cellular content in the adult male pituitary.
Fig 3. Cell population volume does not change in Foxg1Cre/+; ARfl/y pituitaries. Subpopulations of pituitary cells stain positive for (A) PRL, (B) GH, (C)
FSH, (D) TSH (E) LH (F) ACTH. (G) When volume is quantified there is no significant difference between control and Foxg1Cre/+; ARfl/y for PRL-positive
lactotrophs (Control 18.4% ±1.6, Foxg1Cre/+; ARfl/y 21.9% ±1.7), GH-positive somatotrophs (Control 12.3% ±1.6, Foxg1Cre/+; ARfl/y 11.6% ±2.3), FSH-positive
gonadotrophs (Control 5.6% ±0.6, Foxg1Cre/+; ARfl/y 5.8% ±1.1), TSH-positive thyrotrophs (Control 5.2% ±0.6, Foxg1Cre/+; ARfl/y 6.2% ±0.7), LH-positive
gonadotrophs (Control 4.8% ±0.8, Foxg1Cre/+; ARfl/y 4.6% ±0.6) and ACTH-positive corticotrophs (Control 3.6% ±0.2, Foxg1Cre/+; ARfl/y 4.7% ±0.7).
doi:10.1371/journal.pone.0121657.g003
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Circulating gonadotrophin levels are unchanged in Foxg1Cre/+; ARfl/y
mice
To empirically determine whether pituitary androgen receptor is required for the control of go-
nadotrophin production and release, expression levels of transcripts encoding pituitary Gnrhr
(the receptor for GnRH) and gonadotrophin subunits, and concentrations of plasma gonado-
trophins were compared between control and Foxg1Cre/+; ARfl/y mice. Gnrhr transcript levels
are significantly reduced (p<0.001) suggesting loss of AR may have altered the sensitivity of
gonadotrophs to GnRH (Fig. 4A). A significant increase in common glycoprotein subunit-α
(Cga, Fig. 4B) is also seen in Foxg1Cre/+; ARfl/y pituitaries compared to controls, whilst no
change is observed in luteinising hormone-β transcript (Lhb, Fig. 4C). Surprisingly, despite
Fig 4. No changes are seen in gonadotrophin mRNAs or circulating hormone levels in Foxg1Cre/+;
ARfl/y mice. (A) There is a significant decrease in transcript of gonadotrophin releasing hormone receptor
(Gnrhr, p<0.001) in the Foxg1Cre/+; ARfl/y pituitary compared to controls. (B) There is a significant increase in
the normalised pituitary transcript for common glycoprotein subunit-α (Cga, p<0.05) in Foxg1Cre/+; ARfl/y s.
(C) There is no significant difference in luteinising hormone-β transcript (Lhb) between controls and Foxg1Cre/
+; ARfl/y s. (D) No significant difference was seen between Foxg1Cre/+; ARfl/y and control plasma levels of LH
(Control 0.93 ±0.20, Foxg1Cre/+; ARfl/y 1.33 ±0.24 ng/ml), (E) There is a significant decrease in the Foxg1Cre/+;
ARfl/y pituitary of follicle stimulating hormone-β transcript (Fshb, p<0.05). (F) No significant difference was
seen between Foxg1Cre/+; ARfl/y and control plasma levels of FSH (Control 30.9 ±3.19, Foxg1Cre/+; ARfl/y
35.72 ±2.31 ng/ml).
doi:10.1371/journal.pone.0121657.g004
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reductions in both Gnrhr and Cga transcription, we observe no change in plasma LH concen-
trations compared to littermate controls (control 0.93 ±0.20, Foxg1Cre/+; ARfl/y 1.33 ±0.24 ng/
ml, Fig. 4D). Follicle stimulating hormone-β (Fshb) transcript is significantly decreased in
Foxg1Cre/+; ARfl/y males compared to controls (Fig. 4E) but again, this i not reflected in a
change in the level of plasma FSH (control 30.9 ±3.19, Foxg1Cre/+; ARfl/y 35.72 ±2.31 ng/ml),
Fig. 4E). Together these data demonstrate that pituitary AR is dispensable for regulation of cir-
culating gonadotrophin concentrations in the male mouse.
Estrogen signalling is thought to be responsible for a proportion of the feedback attributed
to testosterone at the hypothalamus and pituitary, and estrogen receptor α (ESR1) levels are
shown to increase in some tissues when AR is ablated or downregulated [28] [29] [16], raising
the possibility that increased or retained estrogen signalling could explain the lack of impact
loss of AR has on circulating gonadotrophin levels. However, no significant difference is seen
in Esr1 transcript levels (Fig. 5A) or ESR1 protein levels (Fig. 5B) in Foxg1Cre/+; ARfl/y pituitar-
ies compared to controls, and expression of Cyp19a1 (aromatase) cannot be detected in either
control or Foxg1Cre/+; ARfl/y male pituitaries (data not shown), suggesting compensation by
modulation of estrogen signalling does not underpin any theoretical ‘rescue’ of circulating
gonadotrophin levels.
Ablation of pituitary AR does not affect some pituitary products
Having demonstrated AR is dispensable for regulation of circulating gonadotrophin levels, we
next asked whether loss of AR impacted other pituitary products. Since previously published
literature has suggested AR plays a role in the regulation of pituitary glucocorticoid receptor
(GR) expression [4], we quantified Gr transcript levels, but no difference is noted between
Foxg1Cre/+; ARfl/y and control animals (Fig. 6A), suggesting pituitary AR is not a major regula-
tor of pituitary GR expression. Since all pituitary endocrine cells express AR (Fig. 1), the ex-
pression levels of transcripts encoding other pituitary hormone subunits and concentrations of
plasma pituitary products were compared between control and Foxg1Cre/+; ARfl/y mice. No dif-
ference is observed in either the transcript for pro-opiomelanocortin (Pomc the precursor
Fig 5. ESR1 transcript and protein levels do not change in Foxg1Cre/+; ARfl/y pituitaries. (A) No
significant difference was seen in Esr1 transcript levels or (B) ESR1 protein levels (normalised to TUBA) in
Foxg1Cre/+; ARfl/y pituitaries compared to controls.
doi:10.1371/journal.pone.0121657.g005
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transcript of ACTH, Fig. 6B) or its circulating form ACTH (control 18.42 ±5.52, Foxg1Cre/+;
ARfl/y 16.30 ±2.97 pg/ml Fig. 6C). Likewise, no difference is observed in either the transcript
for growth hormone (Gh, Fig. 6D) or circulating GH (control 1.48 ±0.51, Foxg1Cre/+; ARfl/y
0.50 ±0.16 ng/ml, Fig. 6E). No change is seen in thyroid-stimulating hormone-β (Tsh, Fig. 6F)
or circulating TSH (control 1.06 ±0.11, Foxg1Cre/+; ARfl/y 1.20 ±0.14 ng/ml, Fig. 6G).
Pituitary AR functions to suppress prolactin production by the male
pituitary
Surprisingly, a significant increase in pituitary prolactin transcript (Prl, Fig. 7A) and a 15-fold
increase in plasma prolactin levels (Control 69.0 ±24.3, Foxg1Cre/+; ARfl/y 1062 ±144.7 pg/ml,
Fig. 7B) are observed in Foxg1Cre/+; ARfl/y mice compared to controls. Furthermore, seminal
Fig 6. No changes are seen in some pituitary hormonemRNAs or circulating products in Foxg1Cre/+; ARfl/y mice. (A) There is no significant difference
in transcript of glucocorticoid receptor (Gr) between Foxg1Cre/+; ARfl/y and control pituitaries. (B) There is no significant difference in transcript of pro-
opiomelanocortin (Pomc) between Foxg1Cre/+; ARfl/y and control pituitaries. (C) No significant difference was seen between Foxg1Cre/+; ARfl/y and control
plasma levels of ACTH (Control 18.42 ±5.52, Foxg1Cre/+; ARfl/y 16.30 ±2.97 pg/ml). (D) There is no significant difference in transcript of growth hormone (Gh),
between Foxg1Cre/+; ARfl/y and control pituitaries. (E) No significant difference was seen between Foxg1Cre/+; ARfl/y and control plasma levels of GH (Control
1.48 ±0.51, Foxg1Cre/+; ARfl/y 0.50 ±0.16 ng/ml). (F) There is no significant difference in transcript of thyroid-stimulating hormone-β (Tsh) between Foxg1Cre/+;
ARfl/y and control pituitaries. (G) No significant difference was seen between Foxg1Cre/+; ARfl/y and control plasma levels of TSH (Control 1.06 ±0.11,
Foxg1Cre/+; ARfl/y 1.20 ±0.14 ng/ml).
doi:10.1371/journal.pone.0121657.g006
Fig 7. Foxg1Cre/+; ARfl/y mice have an increase in circulating prolactin and heavier seminal vesicles. (A) There is a significant increase of prolactin
transcript (Prl, p<0.01) in the Foxg1Cre/+; ARfl/y pituitary compared to control. (B) Plasma prolactin levels were significantly increased in Foxg1Cre/+; ARfl/y
mice (1062 ±144.7 pg/ml) compared to controls (69.0 ±24.3 pg/ml, p<0.001). (C) Adult Foxg1Cre/+; ARfl/y mice have a significant increase in seminal vesicle
weight (p<0.01).
doi:10.1371/journal.pone.0121657.g007
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vesicle weight is significantly increased in Foxg1Cre/+; ARfl/y mice (Fig. 7C), consistent with
other rodent models of hyperprolactinaemia [30, 31].
The percentage of lactotrophs expressing ESR1 does not change in
Foxg1Cre/+; ARfl/y mice
Since estradiol is the main stimulator of lactotroph prolactin production [32], we next sought
to determine whether ESR1 expression specifically in lactotrophs is altered in Foxg1Cre/+; ARfl/y
males after embryonic AR ablation. Double immunohistochemistry was performed for ESR1
and PRL (Fig. 8A) however, no significant difference is found in the percentage of lactotrophs
that express ESR1 (Control 74.2%, Foxg1Cre/+; ARfl/y 73.1%, Fig. 8B).
Discussion
Production of testosterone by testicular Leydig cells is tightly regulated by the hypothalamic-pi-
tuitary-gonadal (HPG) axis, forming a homeostatic negative feedback loop, but exactly how
this is affected is not entirely understood. In this study we examined a mouse line with ablation
of androgen receptor in the pituitary (Foxg1Cre/+; ARfl/y) to empirically determine the role of
pituitary androgen receptor in the control of male pituitary hormone production. Foxg1-Cre
was active from fetal life and ablated androgen receptor in the pituitary. Surprisingly this re-
sulted in no change in circulating testosterone levels, questioning the currently accepted para-
digm of testosterone-mediated feedback at the level of the pituitary. Further to this
observation, in this study we demonstrate that circulating gonadotrophin levels are unaffected
by loss of pituitary AR, suggesting androgens do not mediate negative feedback on the HPG
axis at the level of the pituitary in males. Instead, we show that pituitary AR is required for re-
pression of prolactin production and release by the male pituitary.
Fig 8. The percentage of lactotrophs expressing ESR1 does not change in Foxg1Cre/+; ARfl/y mice. (A) A subpopulation of PRL-positive lactotrophs
(blue) stain positive for ESR1 (green). Insets showmagnifications of ESR1 positive and negative cells, and no-primary controls. (B) No significant difference
was found in the percentage of lactotrophs that express ESR1 (Control 74.2% ±2.2, Foxg1Cre/+; ARfl/y 73.1% ± 5.8).
doi:10.1371/journal.pone.0121657.g008
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The majority of Cre Recombinase mouse lines target multiple tissues; as such empirical es-
tablishment of sites of targeting is an essential step in validating the utility of any given line as
fit for purpose [33]. Foxg1-Cre is active in the developing brain in the telencephalon, anterior
optic vesicle, otic vesicle, facial and head ectoderm, olfactory epithelium, mid–hindbrain junc-
tion, and pharyngeal pouches [19]. Whilst these structures do not contribute towards the hypo-
thalamus, Foxg1-Cre is active in Rathke’s pouch (the anlage of the pituitary) from e10 and
previous studies use Foxg1-Cre to ablate a floxed gene of interest in the pituitary but not the
hypothalamus [17, 18]. In addition, Foxg1-Cre is also expressed ectopically in some tissues out-
side of the brain, although the use of mice with 129SvJ and C57BL/6 backgrounds (as in the
study) is shown to limit this [19]. We have ourselves previously used Foxg1-Cre to ablate an-
drogen receptor action from the caput epididymal epithelium (CEARKO) [16]. In this case, the
epididymal effects we observe were independently confirmed in a second model that did not
have pituitary AR ablation [34], suggesting a localised impact of AR ablation at this distal site,
with no impact on the central HPG axis. Given this, and the observation that Foxg1-Cre does
not target the hypothalamus or the gonad, but only targets the pituitary component of the
HPG axis, we conclude that, in addition to its utility for investigating epididymal AR function,
the Foxg1Cre/+; ARfl/y mouse model also provides a unique opportunity to determine the role of
AR-signalling in the male pituitary.
Role of steroid hormone receptors in gonadotrophin release
The male HPG axis paradigm is centred on testosterone providing a negative feedback repres-
sion at both the hypothalamus (GnRH production) and pituitary (LH production). Our data
show no change in circulating LH or testosterone [16] levels when AR is selectively genetically
ablated from the male mouse pituitary. One explanation is that AR signalling, though dispens-
able at the pituitary level is required at the hypothalamic level. Since GnRH-producing neurons
do not express AR [35] the level of hypothalamic repression must be upstream of GnRH pro-
duction, potentially at the level of kisspeptin-producing neurons, which do express AR [36]. If
AR is indeed dispensable at the pituitary level for control of the gonadotrophins, the possibility
exists that gonadal steroid feedback is through aromatisation of androgen to estrogen and sub-
sequent signalling through ERα. However, the evidence for this is conflicting with some studies
reporting that circulating LH levels are unaltered in global ERα knockout mice, [37, 38] while
others report an increase in circulating LH [39]. Some studies suggest that only exogenous an-
drogens can supress the increase in circulating LH levels following castration of male mice
[39], others suggest estrogens are required [37]. The phenotype of global ERα knockout mice is
complicated by ablation in the efferent ducts that renders sperm non-functional post epididy-
mal transit, so this model cannot be used to define if HPG effects contribute towards their
infertility. Two models of pituitary-specific ERKO males have been noted to be ‘fertile’ [40, 41],
although no further characterisation of their reproductive parameters was undertaken. Global
ERβ knockout mice do not appear to have defects in their HPG axis [42], so it is unlikely that
estrogen signalling in the male hypothalamic-pituitary unit is via ERβ. Even if normal pituitary
feedback is maintained by ERα in the absence of AR, our data show that there is no compensa-
tory upregulation of ERαmRNA or protein in the Foxg1Cre/+; ARfl/y. We can also not identify
aromatase transcript in the control or Foxg1Cre/+; ARfl/y male mouse pituitary, suggesting that
the synthesis of estrogen that may be involved in the pituitary feedback is at a distal site. This is
contrary to data in male rats [43] which do express aromatase.
Interestingly, levels of gonadotrophin-releasing hormone receptor (Gnrhr) transcript are
significantly reduced in the Foxg1Cre/+; ARfl/y compared to controls. This could potentially be a
site of androgen feedback by decreasing the number of pituitary receptors for GnRHR to bind
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and stimulate a response. However, this is contrary to published literature which shows that
castration has no effect on pituitary GnRHR levels in the mouse [44], and despite this reduc-
tion in Gnrhr, we show that circulating gonadotrophin levels do not change. Interestingly, a re-
cently published model of specific androgen receptor ablation in gonadotrophs in female mice
also showed that basal LH level is not changed, although pre-ovulatory LH surge is decreased
[45]. Basal and surge FSH levels in these females are also decreased, indicating that the role of
AR in gonadotrophs may be sexually dimorphic.
Role of AR in other pituitary cell types
The HPG axis paradigm focuses on androgen receptor feedback to pituitary gonadotrophs. De-
spite this, our results show that a sub-population of all other pituitary endocrine cell types ex-
press androgen receptor, implying that androgen signalling is involved in their function. A role
for pituitary AR in the regulation of pituitary glucocorticoid receptor expression has been pos-
tulated by Miyamoto et al [4]. The authors set out to explore the molecular mechanism behind
late-onset obesity in androgen receptor knock-out (ARKO) mice, which they suggest is caused
by a hyper-corticoid state, driven by high levels of pituitary-derived ACTH as a consequence of
impairment in the hypothalamic-pituitary-adrenal (HPA) axis. Using a luciferase reporter
assay in a pituitary cell culture system, the authors suggest that GR expression is under positive
control by the AR, and they arrive at the conclusion that AR functions in the negative-feedback
regulation of glucocorticoid production by up-regulating GR expression in the pituitary. How-
ever, these conclusions are not supported by data from the Foxg1Cre/+; ARfl/y mouse. There are
two possibilities to explain this discrepancy. Firstly, the mouse model used has a total ablation
of AR, which extends the possibility that the phenotype is a result of AR ablation in another
cell/tissue type. Second, the use of a cell culture system does not take into account the behav-
iour of pituitary cells as a network in vivo.
The hypothalamic-pituitary unit is sexually dimorphic and structural and functional differ-
ences between males and females are potentiated by steroid exposure both neonatally and at
puberty. An example of neonatal steroids affecting development is the oxytocin pulse generator
that is neonatally inactivated in males as testicular testosterone is aromatised into estrogen and
acts via ERα to cause the neurons to undergo apoptosis. Females produce no gonadal steroids
at this age so the neurons persist [46]. The cellular composition of the anterior pituitary does
not differ between the sexes until after pubertal onset when females begin to develop larger an-
terior pituitaries with a higher percentage of lactotrophs, while pituitaries of males contain a
higher percentage of somatotrophs [47]. This dimorphism is due to differences in both the neo-
natal and postpubertal steroid milieu. In Foxg1Cre/+; ARfl/y mice there is no change in somato-
troph volume, and no significant difference in circulating GH levels, implying that pituitary
androgen receptor is not involved in the development of this dimorphism.
The most striking result identified in the Foxg1Cre/+; ARfl/y mouse was the increase in both
pituitary transcript and serum hormone prolactin levels, which validates a previously published
postulation of androgen repression of prolactin release [48]. Control of serum prolactin levels
is via a balance between stimulation by estrogen and inhibition by dopamine produced by the
tuberoinfundibular dopaminergic neurones of the hypothalamus [32, 49]. Estrogen and dopa-
mine antagonise each other to regulate lactotroph endocrine functions including the secretion
and synthesis of prolactin, lactotroph proliferation and gene expression. DHT has previously
been shown to reverse the stimulatory effect of estradiol on PrlmRNA levels in rats [50], which
supports our observation of prolactin mRNA and protein increase when androgen-signalling
repression is removed. It is yet to be determined if this repression is directly through androgen
receptor binding to the prolactin promoter or through an indirect mechanism in adulthood.
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Male rats have been observed to have fewer lactotrophs than females [47]. Neonatal orchi-
dectomy of males resulted in an increase of lactotrophs, but adult orchidectomy did not change
this number, implying that prepubertal gonadal steroid hormones are involved in regulation of
lactotroph specification. In our model of pituitary androgen receptor ablation, we do not see a
change in relative cell volume despite the change in serum prolactin so there is unlikely to be a
developmental programming effect on lactotroph number potentiated by AR. This may be be-
cause signalling via estrogen is instead responsible for the number of lactotrophs and orchi-
dectomy of rats removes both androgens and androgens as the source of estrogen
through aromatisation.
Despite its well-characterised role in lactogenesis in female mammals, the role of prolactin
in males is ill defined. Prolactin treatment has been shown to increase testosterone secretion
and endogenous prolactin is required for the complete expression of the stimulatory action of
LH on T secretion in adult male rats [51]. Both prolactin [52] and prolactin receptor [53]
knock-out male mice are fertile suggesting that prolactin does not have any vital effects on
male fertility, but prolactin knock-out males display reduced LH levels and weights of seminal
vesicles and ventral prostate suggesting it may have a trophic effect on these organs. Clinical
cases of hyperprolactinaemia associated with prolactinomas report low testosterone, decreased
libido and erectile dysfunction [54] as well as low sperm count [55]. Mice with induced hyper-
prolactinaemia show increased seminal vesicle weight [30, 31], which is also seen in the
Foxg1Cre/+; ARfl/y.
Despite AR expression being present in all pituitary cell types, there was limited effect of AR
ablation in most cell types other than the striking effect on prolactin secretion. Volume of pitu-
itary cell types as a percentage of the anterior lobe does not change; there are also no gross dif-
ferences between morphology and size of pituitaries of control and Foxg1Cre/+; ARfl/y mice.
Ablation of AR from the embryonic pituitary gland (as occurs in this model) means that the
Foxg1Cre/+; ARfl/y pituitary has developed without exposure to androgens (although any effects
on development from aromatisation to estrogen would still have occurred). Because of this it is
difficult to elucidate whether any changes are due to a change in development of the pituitary
or an acute effect of the lack of AR signalling. Addressing this would require a model of adult-
onset genetic ablation of pituitary androgen receptor.
In conclusion, this study provides new insight into the regulation of pituitary endocrine
hormones by androgens. It is a central paradigm of male reproductive biology that androgens
act at both the hypothalamus and pituitary to repress the release of LH. However growing evi-
dence (including that generated in this study) demonstrates that the feedback mechanism is in-
dependent of AR in the pituitary. The results we present here also strongly suggest a role of AR
is to repress prolactin secretion in males, and that ablating AR from the pituitary removes this
repression resulting in a novel model of hyperprolactinaemia.
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